A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. The gene discussed is JAK1; the disease is proteosome-associated autoinflammatory syndrome.